Liquidity and Capital Resources	3 Months Ended
Mar. 31, 2016
Liquidity and Capital Resources [Abstract]
Liquidity and Capital Resources	11. Liquidity and Capital Resources At March 31, 2016, we had cash and cash equivalents of approximately $68.2 million. On February 6, 2016, we announced the signing of a long-term loan agreement with Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. for up to $40.0 million in financing, of which we received $25.0 million (see Note 6). Management believes that our current cash and cash equivalents, along with the additional drawdown of the remaining $15.0 million from the long-term loan mentioned above, will be sufficient to fund its operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2016 and the first three months of 2017 of approximately $63.0 million, which includes approximately $32.6 million for its clinical programs for aldoxorubicin, approximately $5.6 million for pre-clinical and development of our new drug candidate, DK049 and for the expansion of our Freiburg operations, approximately $5.4 million for general operation of its clinical programs (which includes a milestone payment to the licensor upon filing an NDA for aldoxorubicin of $1.5 million), approximately $16.3 million for other general and administrative expenses, which includes pre-commercialization activies for aldoxorubicin, and approximately $3.1 million for interest and payments on the term loan. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections. If we obtain marketing approval and successfully commercializes aldoxorubicin or other product candidates, we anticipate it could take several years for us to generate significant recurring revenue. We will be dependent on future financing and possible strategic partnerships until such time, if ever, as we can generate significant recurring revenue. We have no additional commitments from third parties to provide any additional financing, and we may not be able to obtain future financing on favorable terms, or at all. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our development programs or clinical trials, seek to license to other companies our product candidates or technologies that we would prefer to develop and commercialize itself, or seek to sell some or all of our assets or merge with or be acquired by another company.

11. Liquidity and Capital Resources

At March 31, 2016, we had cash and cash equivalents of approximately $68.2 million. On February 6, 2016, we announced the signing of a long-term loan agreement with Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P. for up to $40.0 million in financing, of which we received $25.0 million (see Note 6). Management believes that our current cash and cash equivalents, along with the additional drawdown of the remaining $15.0 million from the long-term loan mentioned above, will be sufficient to fund its operations for the foreseeable future. The estimate is based, in part, upon our currently projected expenditures for the remainder of 2016 and the first three months of 2017 of approximately $63.0 million, which includes approximately $32.6 million for its clinical programs for aldoxorubicin, approximately $5.6 million for pre-clinical and development of our new drug candidate, DK049 and for the expansion of our Freiburg operations, approximately $5.4 million for general operation of its clinical programs (which includes a milestone payment to the licensor upon filing an NDA for aldoxorubicin of $1.5 million), approximately $16.3 million for other general and administrative expenses, which includes pre-commercialization activies for aldoxorubicin, and approximately $3.1 million for interest and payments on the term loan. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections.

If we obtain marketing approval and successfully commercializes aldoxorubicin or other product candidates, we anticipate it could take several years for us to generate significant recurring revenue. We will be dependent on future financing and possible strategic partnerships until such time, if ever, as we can generate significant recurring revenue. We have no additional commitments from third parties to provide any additional financing, and we may not be able to obtain future financing on favorable terms, or at all. If we fail to obtain sufficient funding when needed, we may be forced to delay, scale back or eliminate all or a portion of our development programs or clinical trials, seek to license to other companies our product candidates or technologies that we would prefer to develop and commercialize itself, or seek to sell some or all of our assets or merge with or be acquired by another company.